BioSpace News Archive

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2022 and provided updates on recent clinical, regulatory, and business progress.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today reported first quarter 2022 financial results and provided a business update.

AUM Biosciences, today announced that it has entered into a clinical trial collaboration and supply agreement with Roche to evaluate AUM001, the Company’s novel, highly selective MNK1/2 inhibitor, in combination with atezolizumab (Tecentriq®), Roche’s anti-PD-L1 therapy, across multiple solid tumor indications, leading with Non-Small Cell Lung Cancer (NSCLC) and Urothelial Cancer (UC).

Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, will present late-breaking interim data from its Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (MG) today at the 14th Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders.

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments.

TriSalus Life Sciences®, an immunotherapy company on a mission to extend and improve the lives of patients living with liver and pancreatic tumors, today announced the enrollment of the first patient in its Pressure-Enabled Regional Immuno-Oncology (PERIO™-02) clinical study.

Utah Medical Products, Inc. announces that its Board of Directors approved a quarterly cash dividend of twenty-nine cents per share of common stock payable on July 6, 2022 to shareholders of record at the close of business on June 17, 2022.

PharmaJet® announced that Darin Zehrung has joined the executive leadership team as Chief Business Development Officer.

Bloom Burton & Co. is pleased to announce the finalists for the 2022 Bloom Burton Award. Bestowed annually and nominated by the public at large, the Bloom Burton Award honours an individual who made the greatest contribution to Canada’s innovative healthcare industry in the previous year.

The industry analysis report is considered a valuable source of information about the global Sodium Bicarbonate Injection industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.